Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

TCMD US Equity

Tactile Systems Technology IncHealth Care · Surgical & Medical Instruments & Apparatus · CIK 1027838 · FY ends Dec 31
$23.85
-0.74 (-3.01%)
USD · as of 2026-08-18 · marketstack
1 registered study · 0 active

Studies where TCMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional · 1 with posted results

Held by 10 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., MARSHALL WACE, LLP, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, +5 more) · FINRA short interest 11.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Flexitouch Treatment for Venous UlcersNCT00847002results2012-07-25Wound HealingRandomized · Open-label · TreatmentNot applicableTerminatedsponsor's stated reason: Lack of EnrollmentDevice: Standard Wound Care, Flexitouch System with Standard Wound CareVenous Ulcer8Aug 2010actual2020-02-12

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19